BML-277, also known as Chk2 Inhibitor II, is a Chk2 (checkpoint kinase 2) inhibitor. BML-277 protects T cells from apoptosis by controlling the response of p53 to radiation-induced DNA breaks. ML-277 has IC50 = 15 nM; Ki = 37 nM. ML-277 shows 1000-fold greater selectivity for the Chk2 serine/threonine kinase than for the Cdk1/B and CK1 kinases (for which IC50 = 12 μM and 17 μM, respectively).
Chk Inhibitors Related Prodcuts:
AZD7762 HCl; Rabusertib (LY2603618); MK-8776; CHIR-124; PF-477736; PD0166285; AZD7762